ArticleeLife2021
Structure of mycobacterial CIII
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- AscF in the mycobacterial CIII-CIV supercomplex lacks metal and nucleotide binding but links malate oxidation to respiration.FEBS letters · 2026Article
- Electron transfer between complexes III and IV in S. cerevisiae mitochondrial membranes.FEBS letters · 2026Article
- The Mycobacterial cyt-Journal of medicinal chemistry · 2026Article
- Inhibitors of cytochromemBio · 2026Article
- The Mycobacterium abscessus cytochrome bcc:aaNature communications · 2026Article
- Exploring the lipoproteome of Parageobacillus thermoglucosidasius.Access microbiology · 2026Article
- Mycobacterial respiratory chain enzymes and growth are inhibited by decylubiquinone.Communications biology · 2025Article
- Remission spectroscopy resolves the mechanism of action of bedaquiline within living mycobacteria.Nature communications · 2025Article
- Cryo-EM of native membranes reveals an intimate connection between the Krebs cycle and aerobic respiration in mycobacteria.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Structural and mechanistic study of a novel inhibitor analogue ofnpj drug discovery · 2025Article
- Inhibition mechanism of potential antituberculosis compound lansoprazole sulfide.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Structure of a dimeric full-length ABC transporter.Nature communications · 2024Article
- A Review of Antibacterial Candidates with New Modes of Action.ACS infectious diseases · 2024Review
- Electron transfer in the respiratory chain at low salinity.Nature communications · 2024Article
- Long-range charge transfer mechanism of the IIINature communications · 2024Article
- Telacebec Interferes with Virulence Lipid Biosynthesis Protein Expression and Sensitizes to Other Antibiotics.Microorganisms · 2023Article
- Cryo-Electron Microscopy Structure of theAntimicrobial agents and chemotherapy · 2023Article
- Imidazopyridine Amides: Synthesis,ACS omega · 2023Article
- Structure of mycobacterial respiratory complex I.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Quinone binding sites of cyt bc complexes analysed by X-ray crystallography and cryogenic electron microscopy.Biochemical Society transactions · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
The imidazopyridine telacebec, also known as Q203, is one of only a few new classes of compounds in more than 50 years with demonstrated antituberculosis activity in humans. Telacebec inhibits the mycobacterial respiratory supercomplex composed of complexes III and IV (CIII
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.